BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Halpin SJ, Hamlin PJ, Greer DP, Warren L, Ford AC. Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience. World J Gastroenterol 2013; 19(7): 1091-1097 [PMID: 23467174 DOI: 10.3748/wjg.v19.i7.1091]
URL: https://www.wjgnet.com/1007-9327/full/v19/i7/1091.htm
Number Citing Articles
1
Bikash Devaraj, Andreas M. Kaiser. Surgical Management of Ulcerative Colitis in the Era of BiologicalsInflammatory Bowel Diseases 2015; 21(1): 208 doi: 10.1097/MIB.0000000000000178
2
Amy L. Lightner, Scott A. Strong. The ASCRS Textbook of Colon and Rectal Surgery2022; : 765 doi: 10.1007/978-3-030-66049-9_45
3
Niharika Nalagatla, Katherine Falloon, Gloria Tran, Nienke Z. Borren, Danny Avalos, Jay Luther, Francis Colizzo, John Garber, Hamed Khalili, Joanna Melia, Matthew Bohm, Ashwin N. Ananthakrishnan. Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysisClinical Gastroenterology and Hepatology 2019; 17(3): 502 doi: 10.1016/j.cgh.2018.06.031
4
Jeanne Tung, Felicity T. Enders, Edward V. Loftus. Response to: Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomyJournal of Crohn's and Colitis 2014; 8(10): 1327 doi: 10.1016/j.crohns.2014.02.020
5
Yoichiro Nuki, Motohiro Esaki, Kouichi Asano, Yuji Maehata, Junji Umeno, Tomohiko Moriyama, Shotaro Nakamura, Takayuki Matsumoto, Takanari Kitazono. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experienceScandinavian Journal of Gastroenterology 2016; 51(6): 700 doi: 10.3109/00365521.2016.1138239
6
J.-H. Chen, J. M. Andrews, V. Kariyawasam, N. Moran, P. Gounder, G. Collins, A. J. Walsh, S. Connor, T. W. T. Lee, C. E. Koh, J. Chang, S. Paramsothy, S. Tattersall, D. A. Lemberg, G. Radford-Smith, I. C. Lawrance, A. McLachlan, G. T. Moore, C. Corte, P. Katelaris, R. W. Leong. Review article: acute severe ulcerative colitis - evidence-based consensus statementsAlimentary Pharmacology & Therapeutics 2016; 44(2): 127 doi: 10.1111/apt.13670
7
Javier P. Gisbert, María Chaparro. Acute severe ulcerative colitis: State of the art treatmentBest Practice & Research Clinical Gastroenterology 2018; : 59 doi: 10.1016/j.bpg.2018.05.007
8
Kymberley Thorne, Laith Alrubaiy, Ashley Akbari, David G. Samuel, Sian Morrison-Rees, Stephen E. Roberts. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporinEuropean Journal of Gastroenterology & Hepatology 2016; 28(4): 369 doi: 10.1097/MEG.0000000000000568
9
Marina Aloi, Giulia D’Arcangelo, Martina Capponi, Federica Nuti, Francesca Vassallo, Fortunata Civitelli, Salvatore Oliva, Giuseppe Pagliaro, Salvatore Cucchiara. Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: Efficacy of infliximab as a rescue therapyDigestive and Liver Disease 2015; 47(6): 455 doi: 10.1016/j.dld.2015.01.156
10
M. B. Sprakes, P. J. Hamlin. Commentary: salvage medical therapy for acute severe colitis - ciclosporin or infliximab?Alimentary Pharmacology & Therapeutics 2013; 38(8): 988 doi: 10.1111/apt.12436
11
Catherine Dong, Marie Metzger, Einar Holsbø, Vittorio Perduca, Franck Carbonnel. Systematic review with meta-analysis: mortality in acute severe ulcerative colitisAlimentary Pharmacology & Therapeutics 2020; 51(1): 8 doi: 10.1111/apt.15592
12
Jeff Chang, Rupert WL Leong. Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposureExpert Opinion on Biological Therapy 2014; 14(1): 27 doi: 10.1517/14712598.2014.853738
13
Marcus Harbord, Rami Eliakim, Dominik Bettenworth, Konstantinos Karmiris, Konstantinos Katsanos, Uri Kopylov, Torsten Kucharzik, Tamás Molnár, Tim Raine, Shaji Sebastian, Helena Tavares de Sousa, Axel Dignass, Franck Carbonnel. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current ManagementJournal of Crohn's and Colitis 2017; 11(7): 769 doi: 10.1093/ecco-jcc/jjx009
14
Matthew C Choy, Dean Seah, David M Faleck, Shailja C Shah, Che-Yung Chao, Yoon-Kyo An, Graham Radford-Smith, Talat Bessissow, Marla C Dubinsky, Alexander C Ford, Leonid Churilov, Neville D Yeomans, Peter P De Cruz. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative ColitisInflammatory Bowel Diseases 2019; 25(7): 1169 doi: 10.1093/ibd/izy383
15
David T. Rubin, Ashwin N. Ananthakrishnan, Corey A. Siegel, Bryan G. Sauer, Millie D. Long. ACG Clinical Guideline: Ulcerative Colitis in AdultsAmerican Journal of Gastroenterology 2019; 114(3): 384 doi: 10.14309/ajg.0000000000000152
16
InfliximabReactions Weekly 2021; 1852(1): 238 doi: 10.1007/s40278-021-94691-5
17
G. Pellino, D. S. Keller, G. M. Sampietro, M. Carvello, V. Celentano, C. Coco, F. Colombo, A. Geccherle, G. Luglio, M. Rottoli, M. Scarpa, G. Sciaudone, G. Sica, L. Sofo, R. Zinicola, S. Leone, S. Danese, A. Spinelli, G. Delaini, F. Selvaggi. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitisTechniques in Coloproctology 2020; 24(5): 397 doi: 10.1007/s10151-020-02175-z
18
Enayatullah Baki, Philipp Zwickel, Anna Zawierucha, Robert Ehehalt, Daniel Gotthardt, Wolfgang Stremmel, Annika Gauss. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitisWorld Journal of Gastroenterology 2015; 21(11): 3282-3290 doi: 10.3748/wjg.v21.i11.3282
19
A. Croft, A. Walsh, J. Doecke, G. Radford-Smith. Commentary: salvage medical therapy for acute severe colitis - ciclosporin or infliximab? Author's replyAlimentary Pharmacology & Therapeutics 2013; 38(8): 989 doi: 10.1111/apt.12475